These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34643782)

  • 1. Imaging appearance of residual HCC following incomplete trans-arterial chemoembolization on contrast-enhanced imaging.
    Polikoff A; Wessner CE; Balasubramanya R; Dulka S; Liu JB; Machado P; Savsani E; Lyshchik A; Shaw CM; Eisenbrey JR
    Abdom Radiol (NY); 2022 Jan; 47(1):152-160. PubMed ID: 34643782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Contrast-Enhanced Ultrasound versus Contrast-Enhanced Magnetic Resonance Imaging for the Diagnosis of Focal Liver Lesions Using the Liver Imaging Reporting and Data System.
    Wang JY; Feng SY; Yi AJ; Zhu D; Xu JW; Li J; Cui XW; Dietrich CF
    Ultrasound Med Biol; 2020 May; 46(5):1216-1223. PubMed ID: 32115307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Washout appearance of hepatocellular carcinomas using standardized contrast-enhanced ultrasound (CEUS) including an extended late phase observation - Real-world data from the prospective multicentre DEGUM study.
    Meitner-Schellhaas B; Jesper D; Goertz RS; Zundler S; Strobel D
    Clin Hemorheol Microcirc; 2023; 84(4):413-424. PubMed ID: 37334585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image fusion with volume navigation of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) for post-interventional follow-up after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinomas (HCC): Preliminary results.
    Ross CJ; Rennert J; Schacherer D; Girlich C; Hoffstetter P; Heiss P; Jung W; Feuerbach S; Zorger N; Jung EM
    Clin Hemorheol Microcirc; 2010; 46(2-3):101-15. PubMed ID: 21135486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast-Enhanced Ultrasound With Perfluorobutane for Hepatocellular Carcinoma Diagnosis: Comparison of Imaging Phases and Diagnostic Criteria.
    Kang HJ; Lee JM; Yoon JH; Yoo J; Kim JH; Park J
    AJR Am J Roentgenol; 2024 Feb; 222(2):e2330156. PubMed ID: 37991335
    [No Abstract]   [Full Text] [Related]  

  • 6. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.
    van der Pol CB; McInnes MDF; Salameh JP; Levis B; Chernyak V; Sirlin CB; Bashir MR; Allen BC; Burke LMB; Choi JY; Choi SH; Forner A; Fraum TJ; Giamperoli A; Jiang H; Joo I; Kang Z; Kierans AS; Kang HJ; Khatri G; Kim JH; Kim MJ; Kim SY; Kim YY; Kwon H; Lee JM; Lewis SC; McGinty KA; Mulazzani L; Park MS; Piscaglia F; Podgórska J; Reiner CS; Ronot M; Rosiak G; Song B; Song JS; Tang A; Terzi E; Wang J; Wang W; Wilson SR; Yokoo T
    Radiology; 2022 Feb; 302(2):326-335. PubMed ID: 34783596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of arterial-phase hyperenhancement and late-phase washout of hepatocellular carcinoma-a meta-analysis of contrast-enhanced ultrasound (CEUS) with SonoVue® and Sonazoid®.
    Ren J; Lu Q; Fei X; Dong Y; D Onofrio M; Sidhu PS; Dietrich CF
    Eur Radiol; 2024 Jun; 34(6):3795-3812. PubMed ID: 37989916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system.
    Li J; Ling W; Chen S; Ma L; Yang L; Lu Q; Luo Y
    Eur J Radiol; 2019 Nov; 120():108685. PubMed ID: 31606712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features.
    Chernyak V; Flusberg M; Law A; Kobi M; Paroder V; Rozenblit AM
    J Comput Assist Tomogr; 2018; 42(1):155-161. PubMed ID: 28806321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma: Comparison of contrast-enhanced ultrasound with multiphase computed tomography.
    Paul SB; Dhamija E; Gamanagatti SR; Sreenivas V; Yadav DP; Jain S; Shalimar ; Acharya SK
    Diagn Interv Imaging; 2017 Mar; 98(3):253-260. PubMed ID: 27692674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma.
    Kang HJ; Lee JM; Yoon JH; Han JK
    Korean J Radiol; 2021 Mar; 22(3):354-365. PubMed ID: 33236540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
    Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
    Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement on gadoxetic acid-enhanced MRI via contrast-enhanced ultrasound using perfluorobutane.
    Bae JS; Lee JY; Suh KS; Hong SK; Yoon JH; Kim YJ; Yu SJ; Lee JH; Cho EJ; Lee YB; Han JK
    Abdom Radiol (NY); 2023 Jul; 48(7):2321-2330. PubMed ID: 37097451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study.
    Cho YZ; Park SY; Choi EH; Baik SK; Kwon SO; Kim YJ; Cha SH; Kim MY
    Clin Mol Hepatol; 2015 Jun; 21(2):165-74. PubMed ID: 26157754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?
    Stocker D; Becker AS; Barth BK; Skawran S; Kaniewska M; Fischer MA; Donati O; Reiner CS
    Eur Radiol; 2020 May; 30(5):2922-2933. PubMed ID: 32020398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can absolute arterial phase hyperenhancement improve sensitivity of detection of hepatocellular carcinoma in indeterminate nodules on CT?
    Zafar S; Elbanna KY; Todd AWM; Guimaraes L; O'Brien C; Goel A; Kim TK; Khalili K
    Eur Radiol; 2024 Apr; 34(4):2256-2268. PubMed ID: 37775590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCCs lacking arterial phase hyperenhancement (APHE) on contrast-enhanced ultrasound (CEUS) - a diagnostic challenge. Findings from the prospective multicenter DEGUM CEUS HCC trial.
    Strobel D; Agaimy A; Jesper D; Zundler S; Schellhaas B
    Ultraschall Med; 2023 Dec; 44(6):606-613. PubMed ID: 36781161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perfluorobutane-enhanced ultrasonography with a Kupffer phase: improved diagnostic sensitivity for hepatocellular carcinoma.
    Hwang JA; Jeong WK; Kang HJ; Lee ES; Park HJ; Lee JM
    Eur Radiol; 2022 Dec; 32(12):8507-8517. PubMed ID: 35705829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
    Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
    Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.